REG - Novacyt S.A. - Notice of Results and Investor Presentation

Novacyt SAAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5078Za&default-theme=true

RNS Number : 5078Z  Novacyt S.A.  08 April 2026

 

Novacyt S.A.

("Novacyt" or the "Company")

 

Notice of results

Investor presentation and CEO/CFO video

 

Paris, France, and Manchester, UK - 8 April 2026 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces that
it will report its audited financial results for the year ended 31 December
2025 on Thursday, 30 April 2026.

 

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and
Steve Gibson, Chief Financial Officer, relating to the FY 2025 results will
take place at 11.00am BST on Thursday, 30 April 2026.

 

The webinar is open to all existing and potential investors, and will consist
of a presentation followed by a Q&A session, held on the Investor Meet
Company platform. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9.00am the day before the meeting or at any time
during the live presentation. Automated French subtitling will be available
throughout the presentation.

 

Investors can sign up for the webinar via:

 

https://www.investormeetcompany.com/novacyt-sa/register-investor
(https://www.investormeetcompany.com/novacyt-sa/register-investor)

 

Investors who already follow NOVACYT S.A. on the Investor Meet Company
platform will automatically be invited.

 

CEO and CFO video

Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer
have recorded a video overview relating to the Company's latest acquisition of
Southern Cross Diagnostics Pty Ltd and the Preferential Subscription Rights
("PSR") Issue, explaining the strategic rationale behind the acquisition while
also expanding on the PSR, why it was undertaken and use of proceeds. Please
see link to video:

https://stream.brrmedia.co.uk/broadcast/69d4c95166d5600014a66924
(https://stream.brrmedia.co.uk/broadcast/69d4c95166d5600014a66924) .

 

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Singer Capital Markets (Joint Broker)                                                                     +44 (0) 20 7496 3000
 Phil Davies / James Fischer / Samed Ethemi

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

 

 

About Novacyt Group (www.novacyt.com (http://www.novacyt.com) )

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries, including Australia, following the recent acquisition of
Southern Cross Diagnostics in March 2026, which has opened new distribution
channels to the life sciences and diagnostics industries in the territory and
the wider Asia-Pacific region. The Company is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth
("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORXDLFBQZLFBBZ



            Copyright 2019 Regulatory News Service, all rights reserved